DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.

Yu Jian Shao Yonglu Chen Mingyue ZhuYuanyuan LiuChen FangMinjun WangPeng SunWeiling FuJing HuangShimei ShengYanshan Huang

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2024)

mice, and substantial body weight reduction and metabolism improvement in DIO mice. DR10627 is a promising agent deserving further investigation for the treatment of type 2 diabetes and obesity.

Keyphrases

high fat diet induced
body weight
insulin resistance
metabolic syndrome
type diabetes
weight gain
physical activity
editorial comment
glycemic control
body mass index